Skip Navigation
Risk Management Plan

Drug Risk Management Plan

Referring to drug risk management actions in the US and Europe, Lotus strictly implements drug risk management plan for specific products per Taiwan authority’s request. Lotus reveals medication documents including general medication safety instructions, notice to medical personnel, and other specific risk precautions. The Company estimates the drug risk management plan periodically to enhance medication safety. (For Taiwan only)

Aclasta®

Aclasta® (Zoledronic acid) 5mg/100ml Solution for Infusion

Drospirenone/Ethinylestradiol

愛己膜衣錠3毫克/0.03毫克(Drospirenone/Ethinylestradiol)

Drospirenone/Ethinylestradiol

愛薇膜衣錠3毫克/0.02毫克(Drospirenone/Ethinylestradiol)

Estetrol Monohydrate 15 mg / Drospirenone 3 mg

ALYSSA 15 mg/ 3 mg Film Coated Tablets

Teriparatide

艾歐骨得注射液(Teriparatide)

Bevacizumab

艾麥思注射劑 (Alymsys concentrate for solution for Infusion)

Lurbinectedin

贊必佳凍晶注射劑 (ZEPZELCA lyophilized powder for solution for infusion)